Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment

被引:77
|
作者
Scott, Clare L. [1 ,2 ]
Becker, Marc A. [3 ]
Haluska, Paul [3 ]
Samimi, Goli [4 ]
机构
[1] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia
[2] Royal Womens Hosp, Melbourne, Vic, Australia
[3] Mayo Clin, Div Med Oncol, Rochester, MN USA
[4] Garvan Inst Med Res, Kinghorn Canc Ctr, St Vincents Clin Sch, Sydney, NSW, Australia
来源
FRONTIERS IN ONCOLOGY | 2013年 / 3卷
基金
英国医学研究理事会;
关键词
ovarian cancer; patient-derived xenografts; pre-clinical models; targeted therapy; clinical trials;
D O I
10.3389/fonc.2013.00295
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite increasing evidence that precision therapy targeted to the molecular drivers of a cancer has the potential to improve clinical outcomes, high-grade epithelial ovarian cancer (OC) patients are currently treated without consideration of molecular phenotype, and predictive biomarkers that could better inform treatment remain unknown. Delivery of precision therapy requires improved integration of laboratory-based models and cutting edge clinical research, with pre-clinical models predicting patient subsets that will benefit from a particular targeted therapeutic. Patient-derived xenografts (PDXs) are renewable tumor models engrafted in mice, generated from fresh human tumors without prior in vitro exposure. PDX models allow an invaluable assessment of tumor evolution and adaptive response to therapy. PDX models have been applied to pre-clinical drug testing and bio-marker identification in a number of cancers including ovarian, pancreatic, breast, and prostate cancers. These models have been shown to be biologically stable and accurately reflect the patient tumor with regards to histopathology, gene expression, genetic mutations, and therapeutic response. However, pre-clinical analyses of molecularly annotated PDX models derived from high-grade serous ovarian cancer (HG-SOC) remain limited. In vivo response to conventional and/or targeted therapeutics has only been described for very small numbers of individual HG-SOC PDX in conjunction with sparse molecular annotation and patient outcome data. Recently, two consecutive panels of epithelial OC PDX correlate in vivo platinum response with molecular aberrations and source patient clinical outcomes. These studies underpin the value of PDX models to better direct chemotherapy and predict response to targeted therapy. Tumor heterogeneity, before and following treatment, as well as the importance of multiple molecular aberrations per individual tumor underscore some of the important issues addressed in PDX models.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies
    Heo, Eun Jin
    Cho, Young Jae
    Cho, William Chi
    Hong, Ji Eun
    Jeon, Hye-Kyung
    Oh, Doo-Yi
    Choi, Yoon-La
    Song, Sang Yong
    Choi, Jung-Joo
    Bae, Duk-Soo
    Lee, Yoo-Young
    Choi, Chel Hun
    Kim, Tae-Joong
    Park, Woong-Yang
    Kim, Byoung-Gie
    Lee, Jeong-Won
    [J]. CANCER RESEARCH AND TREATMENT, 2017, 49 (04): : 915 - 926
  • [2] Correlation between tumografts in patient-derived xenograft models and clinical features in epithelial ovarian cancer
    Chung, Y. S.
    Lee, J. Y.
    Kim, S.
    Kim, S. W.
    Kim, Y. T.
    Nam, E. J.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 661 - 661
  • [3] Patient-derived xenograft models in cancer therapy: technologies and applications
    Yihan Liu
    Wantao Wu
    Changjing Cai
    Hao Zhang
    Hong Shen
    Ying Han
    [J]. Signal Transduction and Targeted Therapy, 8
  • [4] Patient-derived xenograft models in cancer therapy: technologies and applications
    Liu, Yihan
    Wu, Wantao
    Cai, Changjing
    Zhang, Hao
    Shen, Hong
    Han, Ying
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [5] Establishment of patient-derived tumor xenograft models of mucinous ovarian cancer
    Ricci, Francesca
    Guffanti, Federica
    Affatato, Roberta
    Brunelli, Laura
    Roberta, Pastorelli
    Fruscio, Robert
    Perego, Patrizia
    Bani, Maria Rosa
    Chiorino, Giovanna
    Rinaldi, Andrea
    Bertoni, Francesco
    Fratelli, Maddalena
    Damia, Giovanna
    [J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (02): : 572 - +
  • [6] Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics
    Liu, Joyce F.
    Palakurthi, Sangeetha
    Zeng, Qing
    Zhou, Shan
    Ivanova, Elena
    Huang, Wei
    Zervantonakis, Ioannis K.
    Selfors, Laura M.
    Shen, Yiping
    Pritchard, Colin C.
    Zheng, Mei
    Adleff, Vilmos
    Papp, Eniko
    Piao, Huiying
    Novak, Marian
    Fotheringham, Susan
    Wulf, Gerburg M.
    English, Jessie
    Kirschmeier, Paul T.
    Velculescu, Victor E.
    Paweletz, Cloud
    Mills, Gordon B.
    Livingston, David M.
    Brugge, Joan S.
    Matulonis, Ursula A.
    Drapkin, Ronny
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (05) : 1263 - 1273
  • [7] Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models
    Eoh, Kyung Jin
    Chung, Young Shin
    Lee, So Hyun
    Park, Sun-Ae
    Kim, Hee Jung
    Yang, Wookyeom
    Lee, In Ok
    Lee, Jung-Yun
    Cho, Hanbyoul
    Chay, Doo Byung
    Kim, Sunghoon
    Kim, Sang Wun
    Kim, Jae-Hoon
    Kim, Young Tae
    Nam, Eun Ji
    [J]. CANCER RESEARCH AND TREATMENT, 2018, 50 (03): : 956 - 963
  • [8] Patient-derived xenograft models—the future of personalised cancer treatment
    Jenna Bhimani
    Katie Ball
    Justin Stebbing
    [J]. British Journal of Cancer, 2020, 122 : 601 - 602
  • [9] Patient-Derived Xenograft Models in Cancer Research
    van Weerden, Wytske M.
    [J]. CANCERS, 2021, 13 (04)
  • [10] Patient-derived xenograft models in hepatopancreatobiliary cancer
    Binhua Pan
    Xuyong Wei
    Xiao Xu
    [J]. Cancer Cell International, 22